$REPH Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Recro Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Recro Pharma, Inc.. Get notifications about new insider transactions in Recro Pharma, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 15 2018 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 10.07 | 200,000 | 2,014,000 | 2,236,025 | 2.4 M to 2.2 M (-8.21 %) |
Mar 13 2018 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Option Exercise | M | 2.47 | 7,500 | 18,525 | 14,500 | |
Mar 13 2018 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Sell | S | 10.45 | 7,500 | 78,347 | 0 | 7.5 K to 0 (-100.00 %) |
Mar 13 2018 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Buy | M | 2.47 | 7,500 | 18,525 | 7,500 | 0 to 7.5 K |
Jan 22 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | M | 0.00 | 5,000 | 0 | 15,000 | |
Jan 22 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 8.89 | 1,575 | 14,002 | 179,231 | 180.8 K to 179.2 K (-0.87 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 0.00 | 5,000 | 0 | 180,806 | 175.8 K to 180.8 K (+2.84 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Option Exercise | M | 0.00 | 6,000 | 0 | 18,000 | |
Jan 22 2018 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Payment of Exercise | F | 8.89 | 1,860 | 16,535 | 31,841 | 33.7 K to 31.8 K (-5.52 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Buy | M | 0.00 | 6,000 | 0 | 33,701 | 27.7 K to 33.7 K (+21.66 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Option Exercise | M | 0.00 | 3,100 | 0 | 9,300 | |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Payment of Exercise | F | 8.89 | 961 | 8,543 | 33,752 | 34.7 K to 33.8 K (-2.77 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Buy | M | 0.00 | 3,100 | 0 | 34,713 | 31.6 K to 34.7 K (+9.81 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Option Exercise | M | 0.00 | 6,000 | 0 | 18,000 | |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Payment of Exercise | F | 8.89 | 1,817 | 16,153 | 27,083 | 28.9 K to 27.1 K (-6.29 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Buy | M | 0.00 | 6,000 | 0 | 28,900 | 22.9 K to 28.9 K (+26.20 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Option Exercise | M | 0.00 | 2,500 | 0 | 7,500 | |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Payment of Exercise | F | 8.89 | 775 | 6,890 | 18,528 | 19.3 K to 18.5 K (-4.01 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Buy | M | 0.00 | 2,500 | 0 | 19,303 | 16.8 K to 19.3 K (+14.88 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Option Exercise | M | 0.00 | 6,400 | 0 | 19,200 | |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Payment of Exercise | F | 8.89 | 2,020 | 17,958 | 28,475 | 30.5 K to 28.5 K (-6.62 %) |
Jan 22 2018 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Buy | M | 0.00 | 6,400 | 0 | 30,495 | 24.1 K to 30.5 K (+26.56 %) |
Jan 08 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 8.84 | 1,579 | 13,956 | 726,055 | 727.6 K to 726.1 K (-0.22 %) |
Jan 08 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 8.84 | 4,732 | 41,822 | 2,172,900 | 2.2 M to 2.2 M (-0.22 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Option Exercise | A | 9.04 | 16,000 | 144,640 | 16,000 | |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Grant | A | 0.00 | 8,000 | 0 | 16,803 | 8.8 K to 16.8 K (+90.88 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Option Exercise | A | 9.04 | 23,000 | 207,920 | 23,000 | |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Grant | A | 0.00 | 11,500 | 0 | 31,613 | 20.1 K to 31.6 K (+57.18 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Mattila Jyrki | Executive VP, Busin ... | Option Exercise | A | 9.04 | 23,000 | 207,920 | 23,000 | |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Mattila Jyrki | Executive VP, Busin ... | Grant | A | 0.00 | 11,500 | 0 | 11,500 | 0 to 11.5 K |
Jan 04 2018 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Option Exercise | A | 9.04 | 32,200 | 291,088 | 32,200 | |
Jan 04 2018 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Grant | A | 0.00 | 16,100 | 0 | 27,701 | 11.6 K to 27.7 K (+138.78 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Option Exercise | A | 9.04 | 40,000 | 361,600 | 40,000 | |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Grant | A | 0.00 | 20,000 | 0 | 24,095 | 4.1 K to 24.1 K (+488.40 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Option Exercise | A | 9.04 | 25,800 | 233,232 | 25,800 | |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Grant | A | 0.00 | 12,900 | 0 | 22,900 | 10 K to 22.9 K (+129.00 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | A | 9.04 | 100,000 | 904,000 | 100,000 | |
Jan 04 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Grant | A | 0.00 | 50,000 | 0 | 175,806 | 125.8 K to 175.8 K (+39.74 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 8.73 | 19,863 | 173,464 | 2,177,632 | 2.2 M to 2.2 M (-0.90 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 9.04 | 18,947 | 171,224 | 2,197,495 | 2.2 M to 2.2 M (-0.85 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 8.73 | 6,635 | 57,943 | 727,634 | 734.3 K to 727.6 K (-0.90 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 9.04 | 6,329 | 57,195 | 734,269 | 740.6 K to 734.3 K (-0.85 %) |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Option Exercise | A | 9.04 | 23,000 | 207,920 | 23,000 | |
Jan 04 2018 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 11,500 | 0 | 11,500 | 0 to 11.5 K |
Jan 02 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 9.19 | 4,110 | 37,791 | 740,598 | 744.7 K to 740.6 K (-0.55 %) |
Jan 02 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 9.44 | 1,980 | 18,690 | 744,708 | 746.7 K to 744.7 K (-0.27 %) |
Jan 02 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 9.19 | 12,305 | 113,142 | 2,216,442 | 2.2 M to 2.2 M (-0.55 %) |
Jan 02 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 9.44 | 5,926 | 55,938 | 2,228,747 | 2.2 M to 2.2 M (-0.27 %) |
Dec 28 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 9.54 | 2,803 | 26,737 | 746,688 | 749.5 K to 746.7 K (-0.37 %) |
Dec 28 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 9.59 | 1,602 | 15,364 | 749,491 | 751.1 K to 749.5 K (-0.21 %) |
Dec 28 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 9.54 | 8,391 | 80,040 | 2,234,673 | 2.2 M to 2.2 M (-0.37 %) |
Dec 28 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 9.59 | 4,798 | 46,016 | 2,243,064 | 2.2 M to 2.2 M (-0.21 %) |
Dec 22 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.80 | 40,000 | 392,000 | 2,436,025 | 2.5 M to 2.4 M (-1.62 %) |
Dec 22 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.84 | 11,000 | 108,240 | 2,476,025 | 2.5 M to 2.5 M (-0.44 %) |
Dec 22 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 10.00 | 25,000 | 250,000 | 2,487,025 | 2.5 M to 2.5 M (-1.00 %) |
Dec 07 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 10.00 | 100,000 | 1,000,000 | 2,605,262 | 2.7 M to 2.6 M (-3.70 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.61 | 100 | 961 | 2,705,262 | 2.7 M to 2.7 M (0.00 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.55 | 100,000 | 955,000 | 2,705,362 | 2.8 M to 2.7 M (-3.56 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.55 | 50,000 | 477,500 | 2,805,362 | 2.9 M to 2.8 M (-1.75 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.62 | 5,000 | 48,100 | 2,855,362 | 2.9 M to 2.9 M (-0.17 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.69 | 500 | 4,845 | 2,860,362 | 2.9 M to 2.9 M (-0.02 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.63 | 6,322 | 60,881 | 2,860,862 | 2.9 M to 2.9 M (-0.22 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.71 | 100 | 971 | 2,867,184 | 2.9 M to 2.9 M (0.00 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.71 | 6,381 | 61,960 | 2,867,284 | 2.9 M to 2.9 M (-0.22 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.66 | 3,764 | 36,360 | 2,873,665 | 2.9 M to 2.9 M (-0.13 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.68 | 700 | 6,776 | 2,877,429 | 2.9 M to 2.9 M (-0.02 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.68 | 2,200 | 21,296 | 2,878,129 | 2.9 M to 2.9 M (-0.08 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.56 | 21,619 | 206,678 | 2,880,329 | 2.9 M to 2.9 M (-0.74 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.68 | 1,500 | 14,520 | 2,901,948 | 2.9 M to 2.9 M (-0.05 %) |
Nov 30 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.71 | 24,430 | 237,215 | 2,903,448 | 2.9 M to 2.9 M (-0.83 %) |
Nov 24 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.37 | 5,900 | 55,283 | 2,927,878 | 2.9 M to 2.9 M (-0.20 %) |
Nov 24 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.48 | 1,450 | 13,746 | 2,933,778 | 2.9 M to 2.9 M (-0.05 %) |
Nov 24 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.39 | 5,800 | 54,462 | 2,935,228 | 2.9 M to 2.9 M (-0.20 %) |
Nov 24 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.31 | 2,051 | 19,095 | 2,941,028 | 2.9 M to 2.9 M (-0.07 %) |
Nov 24 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.32 | 2,913 | 27,149 | 2,943,079 | 2.9 M to 2.9 M (-0.10 %) |
Nov 24 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.36 | 3,088 | 28,904 | 2,945,992 | 2.9 M to 2.9 M (-0.10 %) |
Nov 24 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.37 | 48,566 | 455,063 | 2,949,080 | 3 M to 2.9 M (-1.62 %) |
Nov 24 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.37 | 2,440 | 22,863 | 2,997,646 | 3 M to 3 M (-0.08 %) |
Nov 24 2017 | REPH | Recro Pharma, Inc. | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 9.50 | 100,000 | 950,000 | 3,000,086 | 3.1 M to 3 M (-3.23 %) |
Oct 02 2017 | REPH | Recro Pharma, Inc. | Myers Diane | Director | Payment of Exercise | F | 9.04 | 2,480 | 22,419 | 8,803 | 11.3 K to 8.8 K (-21.98 %) |
Oct 02 2017 | REPH | Recro Pharma, Inc. | Myers Diane | Director | Buy | M | 0.00 | 8,000 | 0 | 11,283 | 3.3 K to 11.3 K (+243.68 %) |
Oct 02 2017 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Payment of Exercise | F | 9.04 | 4,649 | 42,027 | 11,601 | 16.3 K to 11.6 K (-28.61 %) |
Oct 02 2017 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Buy | M | 0.00 | 15,000 | 0 | 16,250 | 1.3 K to 16.3 K (+1,200.00 %) |
Oct 02 2017 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Payment of Exercise | F | 9.04 | 4,649 | 42,027 | 20,113 | 24.8 K to 20.1 K (-18.77 %) |
Oct 02 2017 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Buy | M | 0.00 | 15,000 | 0 | 24,762 | 9.8 K to 24.8 K (+153.66 %) |
Oct 02 2017 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 9.04 | 9,794 | 88,538 | 125,806 | 135.6 K to 125.8 K (-7.22 %) |
Oct 02 2017 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 0.00 | 31,100 | 0 | 135,600 | 104.5 K to 135.6 K (+29.76 %) |
Oct 02 2017 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Financial Off ... | Payment of Exercise | F | 9.04 | 1,905 | 17,221 | 4,095 | 6 K to 4.1 K (-31.75 %) |
Oct 02 2017 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Financial Off ... | Buy | M | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
Oct 02 2017 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Buy | M | 0.00 | 2,000 | 0 | 10,000 | 8 K to 10 K (+25.00 %) |
Aug 21 2017 | REPH | Recro Pharma, Inc. | Mattila Jyrki | Executive VP, Busin ... | Option Exercise | A | 0.00 | 12,000 | 0 | 12,000 | |
Aug 21 2017 | REPH | Recro Pharma, Inc. | Mattila Jyrki | Executive VP, Busin ... | Option Exercise | A | 6.98 | 75,000 | 523,500 | 75,000 | |
Jun 14 2017 | REPH | Recro Pharma, Inc. | Flynn James E | 10% Owner | Sell | S | 6.25 | 68,000 | 425,000 | 1,176,685 | 1.2 M to 1.2 M (-5.46 %) |
Jun 14 2017 | REPH | Recro Pharma, Inc. | Flynn James E | 10% Owner | Sell | S | 6.59 | 32,447 | 213,826 | 1,244,685 | 1.3 M to 1.2 M (-2.54 %) |
Jun 14 2017 | REPH | Recro Pharma, Inc. | Flynn James E | 10% Owner | Sell | S | 6.74 | 10,000 | 67,400 | 1,277,132 | 1.3 M to 1.3 M (-0.78 %) |
Jun 09 2017 | REPH | Recro Pharma, Inc. | Flynn James E | 10% Owner | Sell | S | 6.99 | 17,245 | 120,543 | 1,287,132 | 1.3 M to 1.3 M (-1.32 %) |
Jun 09 2017 | REPH | Recro Pharma, Inc. | Flynn James E | 10% Owner | Sell | S | 7.09 | 45,623 | 323,467 | 1,304,377 | 1.4 M to 1.3 M (-3.38 %) |
Jun 07 2017 | REPH | Recro Pharma, Inc. | Lake Ryan David | Senior VP, Finance ... | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
Jun 07 2017 | REPH | Recro Pharma, Inc. | Lake Ryan David | Senior VP, Finance ... | Option Exercise | A | 7.58 | 65,000 | 492,700 | 65,000 | |
May 16 2017 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Option Exercise | A | 0.00 | 13,274 | 0 | 13,274 | |
May 16 2017 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Option Exercise | A | 0.00 | 13,274 | 0 | 13,274 | |
May 16 2017 | REPH | Recro Pharma, Inc. | Flynn Karen | Director | Option Exercise | A | 0.00 | 13,274 | 0 | 13,274 | |
May 16 2017 | REPH | Recro Pharma, Inc. | ALTOMARI ALFRED | Director | Option Exercise | A | 0.00 | 13,274 | 0 | 13,274 | |
May 16 2017 | REPH | Recro Pharma, Inc. | Ashton William | Director | Option Exercise | A | 0.00 | 13,274 | 0 | 13,274 | |
May 16 2017 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Option Exercise | A | 0.00 | 13,274 | 0 | 13,274 | |
May 15 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.40 | 73,930 | 547,112 | 1,902,380 | 2 M to 1.9 M (-3.74 %) |
May 15 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.40 | 436,070 | 3,227,092 | 1,976,310 | 2.4 M to 2 M (-18.08 %) |
May 11 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.96 | 1,304 | 10,386 | 2,412,380 | 2.4 M to 2.4 M (-0.05 %) |
May 11 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.96 | 7,696 | 61,296 | 2,413,684 | 2.4 M to 2.4 M (-0.32 %) |
May 11 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.77 | 1,088 | 8,457 | 2,421,380 | 2.4 M to 2.4 M (-0.04 %) |
May 11 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.77 | 6,412 | 49,839 | 2,422,468 | 2.4 M to 2.4 M (-0.26 %) |
May 11 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.64 | 33,070 | 252,493 | 2,428,880 | 2.5 M to 2.4 M (-1.34 %) |
May 11 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.64 | 195,059 | 1,489,295 | 2,461,950 | 2.7 M to 2.5 M (-7.34 %) |
May 05 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.69 | 29,160 | 224,270 | 2,657,009 | 2.7 M to 2.7 M (-1.09 %) |
May 05 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.69 | 172,000 | 1,322,852 | 2,686,169 | 2.9 M to 2.7 M (-6.02 %) |
May 05 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.79 | 2,340 | 18,235 | 2,858,169 | 2.9 M to 2.9 M (-0.08 %) |
May 05 2017 | REPH | Recro Pharma, Inc. | Stonepine Capital Management, ... | 10% Owner | Sell | S | 7.79 | 13,808 | 107,604 | 2,860,509 | 2.9 M to 2.9 M (-0.48 %) |
Mar 16 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 7.93 | 3,170 | 25,125 | 751,093 | 754.3 K to 751.1 K (-0.42 %) |
Mar 16 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 8.01 | 6,399 | 51,270 | 754,263 | 760.7 K to 754.3 K (-0.84 %) |
Mar 16 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 8.04 | 5,454 | 43,848 | 760,662 | 766.1 K to 760.7 K (-0.71 %) |
Mar 16 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 7.93 | 9,488 | 75,200 | 2,247,922 | 2.3 M to 2.2 M (-0.42 %) |
Mar 16 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 8.01 | 19,161 | 153,522 | 2,257,410 | 2.3 M to 2.3 M (-0.84 %) |
Mar 16 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 8.04 | 16,328 | 131,271 | 2,276,571 | 2.3 M to 2.3 M (-0.71 %) |
Mar 06 2017 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 7.63 | 20,000 | 152,600 | 20,000 | |
Feb 21 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 7.59 | 3,334 | 25,312 | 766,116 | 769.5 K to 766.1 K (-0.43 %) |
Feb 21 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 7.59 | 9,983 | 75,791 | 2,292,899 | 2.3 M to 2.3 M (-0.43 %) |
Feb 17 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 7.86 | 3,293 | 25,874 | 2,302,882 | 2.3 M to 2.3 M (-0.14 %) |
Feb 17 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 7.88 | 6,479 | 51,055 | 2,306,115 | 2.3 M to 2.3 M (-0.28 %) |
Feb 17 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 7.96 | 2,293 | 18,243 | 2,312,594 | 2.3 M to 2.3 M (-0.10 %) |
Feb 17 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 7.86 | 1,100 | 8,643 | 769,450 | 770.6 K to 769.5 K (-0.14 %) |
Feb 17 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 7.88 | 2,164 | 17,052 | 770,550 | 772.7 K to 770.6 K (-0.28 %) |
Feb 17 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 7.96 | 766 | 6,094 | 772,714 | 773.5 K to 772.7 K (-0.10 %) |
Feb 15 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 7.97 | 2,651 | 21,130 | 773,480 | 776.1 K to 773.5 K (-0.34 %) |
Feb 15 2017 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 7.97 | 7,937 | 63,261 | 2,314,887 | 2.3 M to 2.3 M (-0.34 %) |
Jan 20 2017 | REPH | Recro Pharma, Inc. | Nichols Donna | CAO/Controller | Option Exercise | A | 0.00 | 7,300 | 0 | 7,300 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | Nichols Donna | CAO/Controller | Option Exercise | A | 7.33 | 12,500 | 91,625 | 12,500 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Option Exercise | A | 7.33 | 15,000 | 109,950 | 15,000 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Option Exercise | A | 0.00 | 24,000 | 0 | 24,000 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Option Exercise | A | 7.33 | 36,000 | 263,880 | 36,000 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Option Exercise | A | 0.00 | 12,400 | 0 | 12,400 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Option Exercise | A | 7.33 | 25,000 | 183,250 | 25,000 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Chief Executive Off ... | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Chief Executive Off ... | Option Exercise | A | 7.33 | 144,700 | 1,060,651 | 144,700 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Option Exercise | A | 0.00 | 24,000 | 0 | 24,000 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Option Exercise | A | 7.33 | 34,800 | 255,084 | 34,800 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Financial Off ... | Option Exercise | A | 0.00 | 25,600 | 0 | 25,600 | |
Jan 20 2017 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Financial Off ... | Option Exercise | A | 7.33 | 35,800 | 262,414 | 35,800 | |
Dec 19 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Buy | P | 6.57 | 3,000 | 19,710 | 7,000 | 4 K to 7 K (+75.00 %) |
Dec 19 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Buy | P | 6.53 | 4,000 | 26,120 | 4,000 | 0 to 4 K |